Evaluation of Usefulness of Bisphosphanate for diffuse sclerosing osteomyelitis of the jaw

Evaluation of Usefulness of Bisphosphanate for diffuse sclerosing osteomyelitis of the jaw - Evaluation of Usefulness of BP for DSO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032089

Enrollment

Registered

2018-04-15

Start date

2018-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Sclerosing Osteomyelitis of the jaw

Interventions

Pamidronate disodium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)over 15 years old 2)written informed consent 3)Performance Status 0 or 1

Exclusion criteria

Exclusion criteria: 1)Patients diagnosed Anti-resorptive agents-related ONJ 2)Patients who received other bisphosphonate.3)Children of 15 years or under. 4)pregnancy, nursing woman or possibly pregnant woman.5)Patients with severe renal disorders(BUN:=<1.5 upper limit of normal,Cr:=<1.5 upper limit of normal) 6)patients who are contraindications for Voltaren

Design outcomes

Primary

Measure	Time frame
Change of Visual Analogue Scale (VAS) of pain after administaration of bisphosphonate	—

Secondary

Measure	Time frame
Safety: general morbidities,side effects SUVmax of the FDF-PET correlation between Bone scintigraphy and pain area	—

Countries

Japan

Contacts

Public ContactTakuya Asaka

Graduate School of Dental Medicine, Hokkaido University Oral Diagnosis and Medicine

asakatakuya@den.hokudai.ac.jp011-706-4280

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026